Skip to main content
Erschienen in: The International Journal of Cardiovascular Imaging 6/2011

01.07.2011 | Original paper

Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold

verfasst von: Salvatore Brugaletta, Hector M. Garcia-Garcia, Scot Garg, Josep Gomez-Lara, Roberto Diletti, Yoshinobu Onuma, Robert Jan van Geuns, Dougal McClean, Dariusz Dudek, Leif Thuesen, Bernard Chevalier, Stephan Windecker, Robert Whitbourn, Cecile Dorange, Karine Miquel-Hebert, Krishnankutty Sudhir, John A. Ormiston, Patrick W. Serruys

Erschienen in: The International Journal of Cardiovascular Imaging | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Implantation of a coronary stent results in a mechanical enlargement of the coronary lumen with stretching of the surrounding atherosclerotic plaque. Using intravascular ultrasound virtual-histology (IVUS-VH) we examined the temporal changes in composition of the plaque behind the struts (PBS) following the implantation of the everolimus eluting bioresorbable vascular scaffold (BVS). Using IVUS-VH and dedicated software, the composition of plaque was analyzed in all patients from the ABSORB B trial who were imaged with a commercially available IVUS-VH console (s5i system, Volcano Corporation, Rancho Cordova, CA, USA) post-treatment and at 6-month follow-up. This dedicated software enabled analysis of the PBS after subtraction of the VH signal generated by the struts. The presence of necrotic core (NC) in contact with the lumen was also evaluated at baseline and follow-up. IVUS-VH data, recorded with s5i system, were available at baseline and 6-month follow-up in 15 patients and demonstrated an increase in both the area of PBS (2.45 ± 1.93 mm2 vs. 3.19 ± 2.48 mm2, P = 0.005) and the external elastic membrane area (13.76 ± 4.07 mm2 vs. 14.76 ± 4.56 mm2, P = 0.006). Compared to baseline there was a significant progression in the NC (0.85 ± 0.70 mm2 vs. 1.21 ± 0.92 mm2, P = 0.010) and fibrous tissue area (0.88 ± 0.79 mm2 vs. 1.15 ± 1.05 mm2, P = 0.027) of the PBS. The NC in contact with the lumen in the treated segment did not increase with follow-up (7.33 vs. 6.36%, P = 0.2). Serial IVUS-VH analysis of BVS-treated lesions at 6-month demonstrated a progression in the NC and fibrous tissue content of PBS.
Literatur
1.
Zurück zum Zitat Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349(14):1315–1323. doi:10.1056/NEJMoa035071349/14/1315[pii] PubMedCrossRef Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349(14):1315–1323. doi:10.​1056/​NEJMoa035071349/​14/​1315[pii] PubMedCrossRef
4.
Zurück zum Zitat Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R (2009) Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 120(2):141–149, 141–142. doi:CIRCULATIONAHA.107.730010 [pii]10.1161/CIRCULATIONAHA.107.730010 Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R (2009) Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 120(2):141–149, 141–142. doi:CIRCULATIONAHA.107.730010 [pii]10.​1161/​CIRCULATIONAHA.​107.​730010
6.
Zurück zum Zitat Sarno G, Onuma Y, Garcia HM, Garg S, Regar E, Thuesen L, Dudek D, Veldhof S, Dorange C, Ormiston JA, Serruys PW (2010) Ivus radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. Catheter Cardiovasc Interv 5:627–632. doi:10.1002/ccd.22332 Sarno G, Onuma Y, Garcia HM, Garg S, Regar E, Thuesen L, Dudek D, Veldhof S, Dorange C, Ormiston JA, Serruys PW (2010) Ivus radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. Catheter Cardiovasc Interv 5:627–632. doi:10.​1002/​ccd.​22332
7.
Zurück zum Zitat Kubo T, Maehara A, Mintz GS, Garcia-Garcia HM, Serruys PW, Suzuki T, Klauss V, Sumitsuji S, Lerman A, Marso SP, Margolis MP, Margolis JR, Foster MC, De Bruyne B, Leon MB, Stone GW (2010) Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound. Am Heart J 159(2):271–277. doi:S0002-8703(09)00880-1 [pii]10.1016/j.ahj.2009.11.008 Kubo T, Maehara A, Mintz GS, Garcia-Garcia HM, Serruys PW, Suzuki T, Klauss V, Sumitsuji S, Lerman A, Marso SP, Margolis MP, Margolis JR, Foster MC, De Bruyne B, Leon MB, Stone GW (2010) Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound. Am Heart J 159(2):271–277. doi:S0002-8703(09)00880-1 [pii]10.​1016/​j.​ahj.​2009.​11.​008
8.
Zurück zum Zitat Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D (2009) A bioabsorbable everolimus-eluting coronary stent system (absorb): 2-year outcomes and results from multiple imaging methods. Lancet 373(9667):897–910. doi:S0140-6736(09)60325-1[pii]10.1016/S0140-6736(09)60325-1 PubMedCrossRef Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D (2009) A bioabsorbable everolimus-eluting coronary stent system (absorb): 2-year outcomes and results from multiple imaging methods. Lancet 373(9667):897–910. doi:S0140-6736(09)60325-1[pii]10.​1016/​S0140-6736(09)60325-1 PubMedCrossRef
10.
Zurück zum Zitat Hausmann D, Lundkvist AJ, Friedrich GJ, Mullen WL, Fitzgerald PJ, Yock PG (1994) Intracoronary ultrasound imaging: intraobserver and interobserver variability of morphometric measurements. Am Heart J 128(4):674–680PubMedCrossRef Hausmann D, Lundkvist AJ, Friedrich GJ, Mullen WL, Fitzgerald PJ, Yock PG (1994) Intracoronary ultrasound imaging: intraobserver and interobserver variability of morphometric measurements. Am Heart J 128(4):674–680PubMedCrossRef
11.
Zurück zum Zitat Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG (2002) Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106(17):2200–2206PubMedCrossRef Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG (2002) Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106(17):2200–2206PubMedCrossRef
12.
Zurück zum Zitat Garcia-Garcia HM, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L, Ormiston JA, Regar E, Serruys PW (2009) Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the absorb clinical trial. EuroIntervention 4(4):443–448PubMedCrossRef Garcia-Garcia HM, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L, Ormiston JA, Regar E, Serruys PW (2009) Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the absorb clinical trial. EuroIntervention 4(4):443–448PubMedCrossRef
13.
Zurück zum Zitat Serruys PW, Onuma Y, Ormiston JA, De Bruyne B, Regar E, Dudek D, Thuesen L, Smith P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia Garcia HM (2010) Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: 6-month clinical and imaging outcomes. Circulation (in press) Serruys PW, Onuma Y, Ormiston JA, De Bruyne B, Regar E, Dudek D, Thuesen L, Smith P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia Garcia HM (2010) Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: 6-month clinical and imaging outcomes. Circulation (in press)
14.
Zurück zum Zitat Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A (2002) Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106(21):2649–2651PubMedCrossRef Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A (2002) Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106(21):2649–2651PubMedCrossRef
15.
Zurück zum Zitat Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL (2002) Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 13(3):183–188PubMedCrossRef Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL (2002) Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 13(3):183–188PubMedCrossRef
17.
Zurück zum Zitat Aoki J, Abizaid AC, Serruys PW, Ong AT, Boersma E, Sousa JE, Bruining N (2005) Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 46(9):1670–1676. doi:S0735-1097(05)01846-2[pii]10.1016/j.jacc.2005.06.076 PubMedCrossRef Aoki J, Abizaid AC, Serruys PW, Ong AT, Boersma E, Sousa JE, Bruining N (2005) Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 46(9):1670–1676. doi:S0735-1097(05)01846-2[pii]10.​1016/​j.​jacc.​2005.​06.​076 PubMedCrossRef
18.
Zurück zum Zitat Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J, Thuesen L, Hamm CW, Veldhof S, Dorange C, Serruys PW (2005) One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (the spirit first trial). EuroIntervention 1(3):266–272. doi:EIJV1I3A44[pii] PubMed Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J, Thuesen L, Hamm CW, Veldhof S, Dorange C, Serruys PW (2005) One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (the spirit first trial). EuroIntervention 1(3):266–272. doi:EIJV1I3A44[pii] PubMed
20.
Zurück zum Zitat Onuma Y, Serruys P, den Heijer P, Joesoef KS, Duckers H, Regar E, Kukreja N, Tanimoto S, Garcia-Garcia HM, van Beusekom H, van der Giessen W, Nishide T (2009) Mahoroba, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. Eur Heart J 30(12):1477–1485. doi:ehp127[pii]10.1093/eurheartj/ehp127 PubMedCrossRef Onuma Y, Serruys P, den Heijer P, Joesoef KS, Duckers H, Regar E, Kukreja N, Tanimoto S, Garcia-Garcia HM, van Beusekom H, van der Giessen W, Nishide T (2009) Mahoroba, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. Eur Heart J 30(12):1477–1485. doi:ehp127[pii]10.​1093/​eurheartj/​ehp127 PubMedCrossRef
22.
Zurück zum Zitat Martinet W, Verheye S, De Meyer GR (2007) Everolimus-induced mtor inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 3(3):241–244. doi:3711[pii] PubMed Martinet W, Verheye S, De Meyer GR (2007) Everolimus-induced mtor inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 3(3):241–244. doi:3711[pii] PubMed
23.
Zurück zum Zitat Onuma Y, Serruys PW, Perkins L, Okamura T, Gonzalo N, Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R Intracoronary optical coherence tomography (oct) and histology at 1 month, at 2, 3 and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human oct images in the absorb trial. Circulation (in press) Onuma Y, Serruys PW, Perkins L, Okamura T, Gonzalo N, Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R Intracoronary optical coherence tomography (oct) and histology at 1 month, at 2, 3 and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human oct images in the absorb trial. Circulation (in press)
25.
Zurück zum Zitat Rodriguez-Granillo GA, Vaina S, Garcia-Garcia HM, Valgimigli M, Duckers E, van Geuns RJ, Regar E, van der Giessen WJ, Bressers M, Goedhart D, Morel MA, de Feyter PJ, Serruys PW (2006) Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies. Int J Cardiovasc Imaging 22(5):621–631. doi:10.1007/s10554-006-9080-0 PubMedCrossRef Rodriguez-Granillo GA, Vaina S, Garcia-Garcia HM, Valgimigli M, Duckers E, van Geuns RJ, Regar E, van der Giessen WJ, Bressers M, Goedhart D, Morel MA, de Feyter PJ, Serruys PW (2006) Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies. Int J Cardiovasc Imaging 22(5):621–631. doi:10.​1007/​s10554-006-9080-0 PubMedCrossRef
Metadaten
Titel
Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold
verfasst von
Salvatore Brugaletta
Hector M. Garcia-Garcia
Scot Garg
Josep Gomez-Lara
Roberto Diletti
Yoshinobu Onuma
Robert Jan van Geuns
Dougal McClean
Dariusz Dudek
Leif Thuesen
Bernard Chevalier
Stephan Windecker
Robert Whitbourn
Cecile Dorange
Karine Miquel-Hebert
Krishnankutty Sudhir
John A. Ormiston
Patrick W. Serruys
Publikationsdatum
01.07.2011
Verlag
Springer Netherlands
Erschienen in
The International Journal of Cardiovascular Imaging / Ausgabe 6/2011
Print ISSN: 1569-5794
Elektronische ISSN: 1875-8312
DOI
https://doi.org/10.1007/s10554-010-9724-y

Weitere Artikel der Ausgabe 6/2011

The International Journal of Cardiovascular Imaging 6/2011 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.